Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Selective inhibition of cyclooxygenase-2 (COX-2) may be associated with an increased risk of thrombotic events, but only limited long-term data have been available for analysis. We report on the cardiovascular outcomes associated with the use of the selective COX-2 inhibitor rofecoxib in a long-term, multicenter, randomized, placebo-controlled, double-blind trial designed to determine the effect of three years of treatment with rofecoxib on the risk of recurrent neoplastic polyps of the large bowel in patients with a history of colorectal adenomas. METHODS: A total of 2586 patients with a history of colorectal adenomas underwent randomization: 1287 were assigned to receive 25 mg of rofecoxib daily, and 1299 to receive placebo. All investigator-reported serious adverse events that represented potential thrombotic cardiovascular events were adjudicated in a blinded fashion by an external committee. RESULTS: A total of 46 patients in the rofecoxib group had a confirmed thrombotic event during 3059 patient-years of follow-up (1.50 events per 100 patient-years), as compared with 26 patients in the placebo group during 3327 patient-years of follow-up (0.78 event per 100 patient-years); the corresponding relative risk was 1.92 (95 percent confidence interval, 1.19 to 3.11; P=0.008). The increased relative risk became apparent after 18 months of treatment; during the first 18 months, the event rates were similar in the two groups. The results primarily reflect a greater number of myocardial infarctions and ischemic cerebrovascular events in the rofecoxib group. There was earlier separation (at approximately five months) between groups in the incidence of nonadjudicated investigator-reported congestive heart failure, pulmonary edema, or cardiac failure (hazard ratio for the comparison of the rofecoxib group with the placebo group, 4.61; 95 percent confidence interval, 1.50 to 18.83). Overall and cardiovascular mortality was similar in the two groups. CONCLUSIONS: Among patients with a history of colorectal adenomas, the use of rofecoxib was associated with an increased cardiovascular risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Rofecoxib (Section 7.6) is an on-target, mechanism-based class effect.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Rofecoxib, a selective COX-2 inhibitor, was withdrawn from the market in 2004 following the VIGOR and APPROVe trials, which revealed a sustained excess of thrombotic cardiovascular events.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Animal efficacy and short-term human safety data had been reassuring; only long-term cardiovascular outcome trials surfaced the signal.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mechanism is generally ascribed to disruption of the prostacyclin–thromboxane balance, with COX-2-dependent vascular prostacyclin suppressed, without a compensatory effect on platelet COX-1-dependent thromboxane A2 production [77,78].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [77]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432103 · Cited by 4,027
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
Antiplatelet Trialists' Collaboration (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 3,126
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
Solomon, S. D., McMurray, J. J. V., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., Anderson, W. F., Zauber, A., Hawk, E., & Bertagnolli, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050405 · Cited by 2,052
The Coxibs, Selective Inhibitors of Cyclooxygenase-2
FitzGerald, G. A., & Patrono, C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200108093450607 · Cited by 1,565
A Randomized Trial of Aspirin to Prevent Colorectal Adenomas
Baron, J. A., Cole, B. F., Sandler, R. S., Haile, R. W., Ahnen, D., Bresalier, R., McKeown-Eyssen, G., Summers, R. W., Rothstein, R., Burke, C. A., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021735 · Cited by 1,416
Self-citationMcAdam, B. F., Catella-Lawson, F., Mardini, I. A., Kapoor, S., Lawson, J. A., & FitzGerald, G. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.1.272 · Cited by 1,305
Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery
Nussmeier, N. A., Whelton, A. A., Brown, M. T., Langford, R. M., Hoeft, A., Parlow, J. L., Boyce, S. W., & Verburg, K. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050330 · Cited by 1,092
Graham, D. J., Campen, D., Hui, R., Spence, M., Cheetham, C., Levy, G., Shoor, S., & Ray, W. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17864-7 · Cited by 913
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis
Jüni, P., Nartey, L., Reichenbach, S., Sterchi, R., Dieppe, P. A., & Egger, M. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17514-4 · Cited by 846
Cited by
Items 501–600 of 1,003
The need for expanded monitoring of adverse events in behavioral health clinical trials
Peterson, A. L., Roache, J. D., Raj, J., & Young-McCaughan, S. (2013) · Contemporary Clinical Trials · doi:10.1016/j.cct.2012.10.009 · Cited by 70
“For example, the risk of cardiovascular events including heart attack and stroke when taking COX-II anti-inflammatory agents such as celecoxib (Celebrex) and rofecoxib (Vioxx) was only appreciated by examining AE monitoring across multiple clinical trials [7, 8].”
BackgroundCapsaicin for Osteoarthritis Pain
Laslett, L. L., & Jones, G. (2014) · Springer eBooks · doi:10.1007/978-3-0348-0828-6_11 · Cited by 70
Diclofenac topical solution compared with oral diclofenac: a pooled safety analysis
Roth, S. H., & Fuller, P. (2011) · Journal of Pain Research · doi:10.2147/jpr.s20965 · Cited by 77
“45]).(20) These and other data led to withdrawal of rofecoxib from the market in 2005.”
Schug, S. A., Joshi, G. P., Camu, F., Pan, S. M., & Cheung, R. Y. (2008) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e31818ca3ac · Cited by 70
Microsomal prostaglandin E synthase-1 is involved in multiple steps of colon carcinogenesis
Sasaki, Y., Kamei, D., Ishikawa, Y., Ishii, T., Uematsu, S., Akira, S., Murakami, M., & Hara, S. (2011) · Oncogene · doi:10.1038/onc.2011.472 · Cited by 71
“Although the inhibition of COX-2mediated PGE2 formation represents a promising chemopreventive strategy for reducing the risk of cancer, the cardiovascular side effects associated with COX-2 inhibitors, which most likely result from the blunting of anti-thrombotic prostacyclin (PGI2), have recently been found to limit…”
BackgroundFive-Year Analysis of the Prevention of Colorectal Sporadic Adenomatous Polyps Trial
Arber, N., Špičák, J., Rácz, I. A., Zavoral, M., Breazna, A., Gerletti, P., Lechuga, M. J., Collins, N. T., Rosenstein, R. B., Eagle, C. J., et al. (2011) · The American Journal of Gastroenterology · doi:10.1038/ajg.2011.116 · Cited by 70
Cyclooxygenase-2 and Gastric Cancer
Thiel, A., Mrena, J., & Ristimaki, A. P. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9312-1 · Cited by 70
Efficacy and safety of a novel synergistic drug candidate, CRx-102, in hand osteoarthritis
Kvien, T. K., Fjeld, E., Slatkowsky-Christensen, B., Nichols, M., Zhang, Y., Prøven, A., Mikkelsen, K., Palm, Ø., Borisy, A. A., & Lessem, J. N. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.074401 · Cited by 73
“11 12 Similar concerns have recently been raised about the cardiovascular safety of non-naproxen NSAIDs, 13 and the efficacy of long-term dosing of NSAIDs in knee OA has also been questioned.”
Chaudhary, N., & Aparoy, P. (2016) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2016.1165736 · Cited by 70
“However, some studies associated with COX-2 selective inhibitors showed increased risk of cardiovascular side effects (Bresalier et al., 2005; Solomon et al., 2005).”
BackgroundCardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease
Adamson, P. D., Anderson, J. A., Brook, R. D., Calverley, P. M. A., Celli, B. R., Cowans, N. J., Crim, C. C., Dixon, I. J., Martínez, F. J., Newby, D. E., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.06.051 · Cited by 74
Fortunati, N. A., Fioravanti, A., Seri, G., Cinelli, S., & Tenti, S. (2015) · International Journal of Biometeorology · doi:10.1007/s00484-015-1030-x · Cited by 70
Neuroimmune–endocrine crosstalk in schizophrenia and mood disorders
Müller, N., & Schwarz, M. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.7.1017 · Cited by 77
Konstantinopoulos, P. A., & Lehmann, D. F. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005278202 · Cited by 70
“The most compelling evidence regarding the cardiovascular risks of rofecoxib was provided by another randomized, double-blind, placebo-controlled clinical trial that assessed the role of rofecoxib (rofecoxib 25 mg daily vs placebo) in adenomatous polyposis prevention (APPROVe trial).(9) The APPROVe trial (Table II) pe…”
BackgroundCyclooxygenase-2 Inhibitors in Colorectal Cancer Prevention: Counterpoint
Jankowski, J., & Hunt, R. (2008) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-0710 · Cited by 70
“Several large trials, including the APPROVe, APC ADAPT, PreSAP trials, and VICTOR have studied COXIBs for secondary prevention in patients successfully cured of colorectal cancer (35-42).”
BackgroundProneoplastic effects of PGE2mediated by EP4 receptor in colorectal cancer
Doherty, G. A., Byrne, S. M., Molloy, E. S., Malhotra, V., Austin, S. C., Kay, E. W., Murray, F. E., & Fitzgerald, D. J. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-207 · Cited by 69
“While more recent studies have confirmed the chemo-preventive activity of COX-2 selective NSAIDs [8-10], it is also clear that long term therapy with COX-2 inhibitors is associated with an unacceptable increase in the risk of cardiovascular events [9,11].”
BackgroundResultCrowell, J. A. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.04.016 · Cited by 73
“Continued investigations with COX-2 inhibitors not only have revealed the recent controversial data regarding cardiovascular safety [13,14], but also have stimulated research and agent development for non-COX-2 targets of COX-2 inhibitors [15] and have coincided with the development of other agents to modulate the ara…”
BackgroundBrownstein, J. S., Sordo, M., Kohane, I. S., & Mandl, K. D. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000840 · Cited by 69
“[9,10,11,12,13,14,15,17,27] Further, mean age at MI appears to”
BackgroundPieringer, H., & Pichler, M. (2010) · QJM · doi:10.1093/qjmed/hcq203 · Cited by 75
“With the introduction of COX-2 inhibitors it became evident that, in comparison with placebo, there was an increased risk for cardiovascular events.(138,139) In addition, NSAIDs and COX-2 inhibitors are associated with unfavorable side effects such as hypertension,(140) congestive heart failure(141) and impaired kidne…”
BackgroundNonsteroidal anti-inflammatory drugs and cardiovascular risk – a matter of indication
Braun, J., Baraliakos, X., & Westhoff, T. H. (2019) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2019.07.012 · Cited by 76
Cyclooxygenase-2: How good is it as a target for cancer chemoprevention?
Hull, M. A. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.04.013 · Cited by 70
Lanas, Á., Baron, J. A., Sandler, R. S., Horgan, K. J., Bolognese, J., Oxenius, B., Quan, H., Watson, D. J., Cook, T. J., Schoen, R. E., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.11.012 · Cited by 69
Self-citationReginster, J., Malmström, K., Mehta, A., Bergman, G., Ko, A. T., Curtis, S., & Reicin, A. S. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.059162 · Cited by 69
Martín Arias, L. H., Martín González, A., Sanz Fadrique, R., & Vazquez, E. S. (2019) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1302 · Cited by 68
Tumour‐induced immune suppression: role of inflammatory mediators released by myelomonocytic cells
Mao, Y., Poschke, I., & Kiessling, R. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12229 · Cited by 65
Therapeutic implications of the prostaglandin pathway in Alzheimer's disease
Cudaback, E., Jorstad, N. L., Yang, Y. J., Montine, T. J., & Keene, C. D. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.014 · Cited by 73
“COX-2 expression in all tissues is tightly controlled and is important in housekeeping roles, including regulation of systemic energy homeostasis [53], postnatal renal development [54], female fertility[55], and maintenance of cardiovascular homeostasis[56], as evidenced by the cardiovascular risks associated with chr…”
BackgroundEgashira, I., Takahashi‐Yanaga, F., Nishida, R., Arioka, M., Igawa, K., Tomooka, K., Nakatsu, Y., Tsuzuki, T., Nakabeppu, Y., Kitazono, T., et al. (2016) · Cancer Science · doi:10.1111/cas.13106 · Cited by 73
The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction
Brophy, J. M., Lévesque, L. E., & Zhang, B. (2006) · Heart · doi:10.1136/hrt.2006.089367 · Cited by 69
Developing Treatments for Chronic Kidney Disease in the 21st Century
Breyer, M. D., & Suszták, K. (2016) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2016.08.001 · Cited by 75
Wang, H., Sheehan, R. P., Palmer, A. C., Everley, R. A., Boswell, S. A., Ron‐Harel, N., Ringel, A. E., Holton, K. M., Jacobson, C. A., Erickson, A. R., et al. (2019) · Cell Systems · doi:10.1016/j.cels.2019.03.009 · Cited by 71
“, 2018), nonsteroidal anti-inflammatory drugs (Bresalier et al., 2005), and proteasome inhibitors (Waxman et al.”
BackgroundLuz, J. G., Antonysamy, S., Kuklish, S. L., Condon, B., Lee, M. R., Allison, D., Yu, X., Chandrasekhar, S., Backer, R. T., Zhang, A., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00330 · Cited by 77
Cannon, C. P., Curtis, S., Bolognese, J. A., & Laine, L. (2006) · American Heart Journal · doi:10.1016/j.ahj.2006.05.024 · Cited by 78
Self-citationTime variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors
Lévesque, L. E. (2006) · Canadian Medical Association Journal · doi:10.1503/cmaj.051679 · Cited by 68
“30, 2004, after investigators in the Adenomatous Polyp Prevention on Vioxx (APPROVe) trial reported a 2-fold increase in cardiovascular toxicity after 18 months of use.(1,2) In contrast, in the Vioxx Gastrointestinal Outcomes Research (VIGOR) study, a similar increase in risk was reported after only 9 months of treatm…”
New insights to the mechanisms underlying atherosclerosis in rheumatoid arthritis
Mahmoudi, M., Aslani, S., Fadaei, R., & Jamshidi, A. R. (2017) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.12999 · Cited by 65
Combating Inflammation in Cardiovascular Disease
Sethwala, A., Goh, I. Y., & Amerena, J. V. (2020) · Heart Lung and Circulation · doi:10.1016/j.hlc.2020.09.003 · Cited by 69
Li, H., Hortmann, M., Daiber, A., Oelze, M. W., Ostad, M. A., Schwarz, P. M., Xu, H., Xia, N., Kleschyov, A. L., Mang, C. F., et al. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.139030 · Cited by 70
“However, serious cardiovascular side effects have been reported for coxibs, including rofecoxib, celecoxib, parecoxib, and valdecoxib (Bresalier et al., 2005; Nussmeier et al., 2005; Solomon et al., 2005).”
BackgroundHamdulay, S., Wang, B., Birdsey, G. M., Ali, F., Dumont, O., Evans, P. C., Haskard, D. O., Wheeler-Jones, C. P. D., & Mason, J. C. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.01.017 · Cited by 71
Mechanisms of endothelial dysfunction during aging: Predisposition to thrombosis
Sepúlveda, C., Palomo, I. F., & Fuentes, E. (2017) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2017.04.011 · Cited by 70
Glucosamine, Chondroitin Sulfate, and the Two in Combination for Painful Knee Osteoarthritis
(2006) · Obstetrics and Gynecology · doi:10.1097/01.aog.0000209485.75921.bd · Cited by 67
The selective COX-2 inhibitor celecoxib modulates sphingolipid synthesis
Schiffmann, S., Sandner, J., Schmidt, R., Birod, K., Wobst, I., Schmidt, H., Angioni, C., Geißlinger, G., & Grösch, S. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m800122-jlr200 · Cited by 66
Roumie, C. L., Choma, N. N., Kaltenbach, L., Mitchel, Jr., Arbogast, P. G., & Griffin, M. R. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1820 · Cited by 65
“Median (25%, 75%) 3 (1, 6) 7 (3, 11) 6 (3, 11) 8 (4, 13) 5 (2, 9) 5 (2, 9) 5 (2, 10) 6 (3, 11)”
Richards, J. B., Joseph, L., Schwartzman, K., Kreiger, N., Tenenhouse, A., & Goltzman, D. (2006) · Osteoporosis International · doi:10.1007/s00198-006-0142-x · Cited by 71
“disorders prior to their association with increased risk of cardiovascular events [3, 4].”
Low-Dose Aspirin, Coxibs, and other NSAIDS: A Clinical Mosaic Emerges
Patrono, C., & Baigent, C. (2009) · Molecular Interventions · doi:10.1124/mi.9.1.8 · Cited by 70
Non-steroidal anti-inflammatory drug use in the elderly
Pilotto, A., Sancarlo, D., Addante, F., Scarcelli, C., & Franceschi, M. (2009) · Surgical Oncology · doi:10.1016/j.suronc.2009.11.014 · Cited by 81
“Several data suggest that the use of coxibs was associated with serious cardiovascular events [23,24].”
BackgroundXue, D., Zheng, Q., Li, H., Qian, S., Zhang, B., & Pan, Z. (2009) · International Orthopaedics · doi:10.1007/s00264-009-0886-y · Cited by 67
“Besides, some studies have suggested that long-term prescription of selective COX-2 inhibitors increased the risk of cardiovascular events [24].”
BackgroundRat paw oedema modeling and NSAIDs: Timing of effects
Công, H. H., Хазиахметова, В. Н., & Zigashina, L. E. (2015) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-150697 · Cited by 65
“There was a hope that newer NSAIDs, selective inhibitors of COX-2, would be safer, but their longer-term use appeared to cause an increased risk of heart attacks and stroke [5].”
BackgroundGrösch, S., Niederberger, E., & Geißlinger, G. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1260544 · Cited by 73
“At the beginning of this century, coxibs are thought to be the gold standard for long-term treatment of patients with RA or OA, a suggestion which was modified when first large trials discovered that long-term treatment with rofecoxib is associated with a significant increase in cardiovascular side effects [64].”
BackgroundSchink, T., Kollhorst, B., Varas‐Lorenzo, C., Arfè, A., Herings, R. M. C., Lucchi, S. R., Romio, S., Schade, R., Schuemie, M. J., Straatman, H., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0203362 · Cited by 72
COX 2 inhibitors, traditional NSAIDs, and the heart
Jüni, P., Reichenbach, S., & Egger, M. (2005) · BMJ · doi:10.1136/bmj.330.7504.1342 · Cited by 67
Wnt signaling and gastrointestinal tumorigenesis in mouse models
Taketo, M. M. (2006) · Oncogene · doi:10.1038/sj.onc.1210058 · Cited by 64
Moore, N. D. (2007) · Clinical Drug Investigation · doi:10.2165/00044011-200727030-00002 · Cited by 64
Management of cardiovascular disease risk in chronic inflammatory disorders
Kaplan, M. J. (2009) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.29 · Cited by 69
Drug-induced gastrointestinal disorders
Philpott, H., Nandurkar, S., Lubel, J. S., & Gibson, P. R. (2013) · Frontline Gastroenterology · doi:10.1136/flgastro-2013-100316 · Cited by 71
Jiang, B., Huang, X., Yao, H., Jiang, J., Wu, X., Jiang, S., Wang, Q., Lu, T., & Xu, J. (2014) · Organic & Biomolecular Chemistry · doi:10.1039/c3ob41936c · Cited by 74
Leung, W. K., Ng, E. K., Chan, F. K. L., Chan, W. Y., Chan, K.-F., Au-Yeung, A., Lam, C. C. H., Lau, J. Y. W., & Sung, J. J. �. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0693 · Cited by 67
Identifying QT prolongation from ECG impressions using a general-purpose Natural Language Processor
Denny, J. C., Miller, R. A., Waitman, L. R., Arrieta, M. A., & Peterson, J. F. (2008) · International Journal of Medical Informatics · doi:10.1016/j.ijmedinf.2008.09.001 · Cited by 63
“For example, recent studies have implicated commonly used medications in the incidence of sudden death[11,37], myocardial infarction[38,39], and second or third degree atrioventricular block[40], each of which could be targets for clinical decision support interventions.”
BackgroundTang, S. Y., Monslow, J., Todd, L., Lawson, J. A., Puré, E., & FitzGerald, G. A. (2014) · Circulation · doi:10.1161/circulationaha.113.007913 · Cited by 64
Glucocorticoids and gut bacteria: “The GALF Hypothesis” in the metagenomic era
Morris, D. J., & Ridlon, J. M. (2017) · Steroids · doi:10.1016/j.steroids.2017.06.002 · Cited by 68
Time-to-Event Analyses for Long-Term Treatments — The APPROVe Trial
Lagakos, S. W. (2006) · New England Journal of Medicine · doi:10.1056/nejmp068137 · Cited by 63
Oral treatment options for degenerative joint disease—presence and future
Steinmeyer, J., & Konttinen, Y. T. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.01.007 · Cited by 74
Zerbini, C. A. F., Ozturk, Z. E., Grifka, J. K., Maini, M., Nilganuwong, S., Morales, R., Hupli, M. T., Shivaprakash, M., Giezek, H., & the Etoricoxib CLBP Study Group (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x75069 · Cited by 67
Cathcart, M. C., Gately, K. A., Cummins, R., Kay, E. W., O'Byrne, K. J., & Pidgeon, G. P. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-25 · Cited by 62
“However, chronic administration of high concentrations of selective COX-2 inhibitors has been associated with an increased risk of adverse cardiovascular events [12-14].”
BackgroundTreating knee osteoarthritis with intra-articular hyaluronans
Brzusek, D., & Petron, D. J. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802490124 · Cited by 67
Wong, C. C., Cheng, K., & Rigas, B. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.191957 · Cited by 78
“92-fold increase in serious thrombotic cardiovascular events (Bresalier et al., 2005).”
BackgroundReding, T., Bimmler, D., Perren, A. A., Sun, L.-K., Fortunato, F., Storni, F., & Graf, R. (2005) · Gut · doi:10.1136/gut.2005.077925 · Cited by 62
Woodling, N. S., & Andreasson, K. I. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00016 · Cited by 63
Coronary Risks Associated with Diclofenac and Other NSAIDs: An Update
Moore, N. D. (2020) · Drug Safety · doi:10.1007/s40264-019-00900-8 · Cited by 70
Chemoprevention of Colorectal Cancer
Raju, R. P., & Cruz-Correa, M. R. (2005) · Diseases of the Colon & Rectum · doi:10.1007/s10350-005-0170-1 · Cited by 64
“In the National Polyp Study, for example, removal of adenomatous polyps followed by surveillance colonoscopy, significantly reduced the incidence of colorectal carcinoma below the rates of the general population.(5) Table 1.”
BackgroundC-reactive protein levels and subsequent cancer outcomes: Results from a prospective cohort study
Helzlsouer, K. J., Erlinger, T. P., & Platz, E. A. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.008 · Cited by 65
Clinical perspectives in drug safety and adverse drug reactions
Pillans, P. I. (2008) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.1.5.695 · Cited by 69
Kardosh, A., Soriano, N., Liu, Y., Uddin, J., Petasis, N. A., Hofman, F. M., Chen, T. C., & Schönthal, A. H. (2005) · Blood · doi:10.1182/blood-2005-07-2819 · Cited by 62
“As a specific substrate, we used GST-I B (1-54), which is a GST-fusion protein containing 54 amino acids from the N-terminus of I B .”
MethodResolution of Gastric Cancer-Promoting Inflammation: A Novel Strategy for Anti-cancer Therapy
Piazuelo, M. B., Riechelmann, R. P., Wilson, K. T., & Algood, H. M. S. (2019) · Current topics in microbiology and immunology · doi:10.1007/978-3-030-15138-6_13 · Cited by 69
van Staa, T. P., Leufkens, H. G. M., Zhang, B., & Smeeth, L. L. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000194 · Cited by 63
“The use of coxibs has now changed following the findings of cardiovascular harm [37].”
BackgroundInfluentialAnalgesics and Anti-inflammatory Medications in Sports: Use and Abuse
Feucht, C. L., & Patel, D. R. (2010) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2010.02.004 · Cited by 66
Risk of stroke associated with nonsteroidal anti-inflammatory drugs
Bavry, A. A., & Park, K. E. (2014) · Vascular Health and Risk Management · doi:10.2147/vhrm.s54159 · Cited by 68
The pharmacology of selective inhibition of COX-2
Großer, T. (2006) · Thrombosis and Haemostasis · doi:10.1160/th06-08-0444 · Cited by 60
“The combined clinical experience is compatible with a prothrombotic effect of the coxibs in situations of elevated thrombotic risk (108) and a gradual increase of risk over extended periods of exposure (22, 107, 109).”
BackgroundHail, N., & Lotan, R. (2009) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200700527 · Cited by 60
The role of basic science in evidence-based medicine
Caze, A. L. (2010) · Biology & Philosophy · doi:10.1007/s10539-010-9231-5 · Cited by 69
van der Linden, M. W., van der Bij, S., Welsing, P. M. J., Kuipers, E. J., & Herings, R. M. C. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.087254 · Cited by 60
Joshi, G. P., Gertler, R., & Fricker, R. (2007) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000286229.05723.50 · Cited by 64
“APPROVe, 2005 (26) 2586 patients with a history of colorectal adenomas Mean duration 33 mo Rofecoxib 25 mg versus placebo APTC thromboembolic events (nonfatal stroke, nonfatal MI, and cardiac death) Rofecoxib versus placebo: 1.”
BackgroundMethodInfluentialGarcía Rodríguez, L. A., González-Pérez, A., Bueno, H., & Hwa, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016780 · Cited by 59
“associated with selective COX-2 inhibitors (coxibs)[1–4], there is growing concern and evidence that NSAIDs predispose to”
BackgroundMethodEsophagogastric cancer: Targeted agents
Ku, G. Y., & Ilson, D. H. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.12.009 · Cited by 63
Novel pharmacological approaches in abdominal aortic aneurysm
Puertas-Umbert, L., Almendra‐Pegueros, R., Jiménez‐Altayó, F., Sirvent, M., Galán, M., Martínez‐González, J., & Rodríguez, C. (2023) · Clinical Science · doi:10.1042/cs20220795 · Cited by 68
Concomitant use of ibuprofen and paracetamol and the risk of major clinical safety outcomes
De Vries, F., Setakis, E., & Van Staa, T. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03705.x · Cited by 57
Kirkby, N. S., Lundberg, M. H., Wright, W. R., Warner, T. D., Paul‐Clark, M. J., & Mitchell, J. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098165 · Cited by 67
Puopolo, A. D., Boice, J. A., Fidelholtz, J., Littlejohn, T. W., Miranda, P., Berrocal, A., Ko, A. T., Cichanowitz, N., & Reicin, A. S. (2007) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2007.05.022 · Cited by 59
Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis
Shephard, R. J. (2011) · Yearbook of Sports Medicine · doi:10.1016/j.yspm.2011.03.009 · Cited by 59
Thompson, P. A., Ashbeck, E. L., Roe, D. J., Fales, L., Buckmeier, J. A., Wang, F., Bhattacharyya, A., Hsu, C., Chow, S., Ahnen, D. J., et al. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw151 · Cited by 59
“The APPROVe, PreSAP, and APC trials all reported statistically significant reductions in adenoma development with a coxib (RR¼ 0.55–0.76) (10–12) and evidence that this effect was short lived after coxib withdrawal (10,11,17).”
BackgroundInfluentialCOX-2 in Cardiovascular Disease
Bishop‐Bailey, D., Mitchell, J. A., & Warner, T. D. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000219672.68024.bc · Cited by 59
Nishida, Y., Kano, K., Nobuoka, Y., & Seo, T. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41725 · Cited by 64
Graff, J., Skarke, C., Klinkhardt, U., Watzer, B., Harder, S., Seyberth, H. W., Geißlinger, G., & Nüsing, R. M. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02782.x · Cited by 58
Lai, Y., Ma, L., Huang, W., Yu, X., Zhang, Y., Ji, H., & Tian, J. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.10.056 · Cited by 61
Cyclooxygenase-2 inhibitors in lung cancer treatment: Bench to bed
Liu, R., Xu, K.-P., & Tan, G. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.11.007 · Cited by 62
Cyclooxygenase- and cytochrome P450-derived eicosanoids in stroke
Huang, H., Al‐Shabrawey, M., & Wang, M.-H. (2015) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2015.12.007 · Cited by 58
“While substantial evidence from clinical trials (Adenoma Prevention with Celecoxib (APC), Adenomatous Polyp Prevention on Vioxx (APPROVe), and Prevention of Colorectal Sporadic Adenomatous Polyps (PreSAP) trial) demonstrate that coxibs reduce or prevent the incidence of colorectal cancer [58], long-term use of rofecox…”
BackgroundThe Role of Cyclooxygenase-2 in Colorectal Carcinogenesis
Liu, Y., Sun, H., Hu, M. S., Zhang, Y., Chen, S., Tighe, S. P., & Zhu, Y. (2016) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2016.09.012 · Cited by 63
“Furthermore, according to three large-scale trials, including the Adenoma Prevention with Celecoxib (APC) trial [105], the Prevention of Colorectal Sporadic Adenomatous Polyps (PreSAP) trial [106] and the Adenomatous Polyp Prevention on Vioxx (APPROVe) trial [107], COXIBs have shown to effectively prevent recurrence o…”
BackgroundThe Eicosanoids, Redox-Regulated Lipid Mediators in Immunometabolic Disorders
de Araújo, A. C. J., Wheelock, C. E., & Haeggström, J. Z. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7332 · Cited by 64
“…AP-PROVe (Adenomatous Polyp Prevention on Vioxx) study, were disclosed, the data indicated a significant risk of thrombotic events, mainly myocardial infarction and stroke among patients taking rofecoxib (Vioxx), which in turn led to an immediate withdrawal of the drug from the market (18).”
Orjales, A., Mosquera, R., López, B., Olivera, R., Labeaga, L., & Nunez, M. T. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.11.079 · Cited by 62
Savage, R. L. (2005) · Drugs & Aging · doi:10.2165/00002512-200522030-00001 · Cited by 58
Ndounga Diakou, L. A., Trinquart, L., Hróbjartsson, A., Barnes, C., Yavchitz, A., Ravaud, P., & Boutron, I. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000043.pub2 · Cited by 58
Signal Detection and Monitoring Based on Longitudinal Healthcare Data
Suling, M., & Pigeot, I. (2012) · Pharmaceutics · doi:10.3390/pharmaceutics4040607 · Cited by 69
“To overcome some of these limitations, and triggered by several severe safety issues in the last years [10–13], programs have been initiated to make beneficial use of large data pools besides spontaneous reports.”
BackgroundNeed to Develop New Nonsteroidal Anti-Inflammatory Drug Formulations
McCarberg, B. H., & Gibofsky, A. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.08.005 · Cited by 64
Metadata
- Authors
- Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., Konstam, M. A., & Baron, J. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- University of North Carolina at Chapel Hill (US)
- Mount Sinai Hospital (CA)
- University of Birmingham (GB)
- Tufts Medical Center (US)
- Dartmouth College (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-03-17
- Volume
- 352
- Issue
- 11
- Pages
- 1092-1102
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2158131645
- Cited by
- 2,519
- References
- 34
- Citations by year
- 2026: 32 · 2025: 25 · 2024: 17 · 2023: 50 · 2022: 48 · 2021: 37 · 2020: 52 · 2019: 56 · 2018: 63 · 2017: 67 · 2016: 85 · 2015: 107 · 2014: 110 · 2013: 117 · 2012: 120
- FWCI
- 219.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Oncology › Colorectal Cancer Screening and Detection
- Keywords
- rofecoxib, cardiovascular adverse events, thrombotic complications, COX-2 inhibitors, colorectal adenoma, colorectal cancer chemoprevention, myocardial infarction, cerebral ischemic events, congestive heart failure, pulmonary edema, cardiovascular mortality
- MeSH terms
- Adult, Aged, Aged, 80 and over, Anti-Inflammatory Agents, Non-Steroidal, Aspirin, Cardiovascular Diseases, Double-Blind Method, Female, Humans, Lactones, Male, Middle Aged, Risk, Sulfones, Thrombosis, Colorectal Neoplasms, Incidence, Proportional Hazards Models, Single-Blind Method, Cyclooxygenase Inhibitors, Adenomatous Polyps, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.